Diabetic retinopathy is the leading cause of preventable blindness in the U.S — yet far too few people who need screening actually receive it. Through his company, Digital Diagnostics, and its flagship product LumineticsCore, Michael and his team have built an FDA-authorized autonomous AI system that brings diabetic retinopathy screening much closer to patients.

In this episode, we discuss how Michael has spent over a decade driving the systemic changes needed to make autonomous AI viable clinically, economically, and ethically.